Researchers have used worm models to understand why proteins clump together in harmful ways, something that has been associated with Alzheimer’s disease.
- The currently agreed-on premise is that the
clumping of certain proteins in the brain is a driving factor for
Alzheimer’s disease.
- Researchers from The Buck Institute for
Research in Novato, CA, now say there are other proteins in these brain
clumps that have been largely ignored so far, and that could also play a
role in the development of this form of dementia.
- Using a worm model, scientists found that both
the natural aging process and beta-amyloid drive some proteins to become
insoluble.
- Researchers used a compound to boost the
quality of mitochondrial health in the proteins that had become insoluble,
helping to delay the toxic effects of beta-amyloid.
Although scientists still
do not know the exact cause of Alzheimer’s
disease, most agree that the clumping of certain proteins —
“The unifying feature of
neurodegenerative diseases of aging is the accumulation of large protein clumps
in the brain which we term insoluble protein aggregates,” Edward Anderton, PhD, a
postdoctoral researcher at The Buck Institute for Research on Aging in
California and co-first author of a study recently published in the journal GeroScience, explained to Medical News
Today.
“In Alzheimer’s disease,
the [beta-amyloid] protein forms aggregates called plaques, and these are
tightly associated with areas of neuronal death and brain inflammation causing
disease,” he noted.
However, Anderton added,
these plaques contain hundreds of additional proteins which have been largely
ignored until now.
For this reason, he and
other researchers from The Buck Institute for Research on Aging in California
decided to examine how the accumulation of insoluble proteins, in general,
might accelerate Alzheimer’s disease.
Using a worm model, scientists found that both the
natural aging process and beta-amyloid drive other proteins to become
insoluble.
Researchers then used a
compound to boost the quality of
Mitochondria,
the so-called powerhouses of the cell, have recently become a focus point in Alzheimer’s research, as
scientist have been trying to see whether “repairing” mitochondria that stop
functioning well with age might help preserve brain health.
What is
protein clumping?
According
to Manish Chamoli, PhD,
research scientist at The Buck Institute for Research on Aging in California
and co-first author of this study, proteins are like tiny machines in our cells
that need to be a specific shape to work correctly.
“Imagine if you had a key that got bent and no
longer fit into its lock — that’s similar to what happens when proteins lose
their shape,” Chamoli explained to MNT. “These
misshapen proteins start sticking together and form insoluble protein
aggregates. Proteins can lose their shape due to various factors like stress,
aging, or damage.”
“Our cells have evolved
ways to either refold the proteins into the correct shape or degrade them when
they’re too damaged to be refolded,” he continued.
In conditions such as
Alzheimer’s disease, however, the brain does not correctly dispose of such
proteins.
“In laboratory organisms,
such as the microscopic worm
“Likewise, it’s well
established that Alzheimer’s disease patients’ brains accumulate protein
aggregates,” he added.
Why do
proteins clump in the brain?
As
insoluble proteins do accumulate in the brain during normal disease-free aging,
Chamoli, Anderton, and their team wanted to know what was the connection
between brain protein clumps in normal aging and Alzheimer’s disease.
Using a worm model, scientists discovered that
beta-amyloid causes a massive amount of insolubility in other proteins,
especially in a subset of proteins researchers called “the core insoluble
proteome.“
According to researchers,
the insoluble proteins found in the core insoluble proteome have already been
linked to other neurodegenerative conditions including Parkinson’s
disease and Huntington’s
disease.
“Data suggest there may be
a causal role for the insoluble proteome in Alzheimer’s disease pathogenesis,”
Anderton said. “For example, insoluble protein extracts from old but not young
animals accelerate the aggregation of [beta-amyloid].”
“We questioned if the
reverse was also true: Can [beta-amyloid] drive the insolubility of proteins
that tend to aggregate during aging? Our data are consistent with the notion
that [beta-amyloid] and age-related changes interact in a destructive
feedforward cycle, leading to an acceleration of protein insolubility in
Alzheimer’s disease.”– Edward Anderton, PhD
Can boosting
mitochondrial health prevent toxic aggregate formation?
Next,
researchers wanted to find a way to potentially reverse how beta-amyloid helps
drive the insolubility of proteins.
As many mitochondrial
proteins become insoluble during natural aging and beta-amyloid influence, they
hypothesized that boosting mitochondrial protein quality might reverse some of
beta-amyloid’s negative effects.
“Mitochondria contain a
specialized energy-producing complex of proteins called the
“It has been known for some time that mitochondria
can be negatively impacted by [beta-amyloid] but we show that this is likely
due to protein insolubility,” he continued. “Luckily, cells possess a way to
recycle damaged mitochondria through a process called
To do this, they chose
“We reasoned that using a
pharmacological approach to clear away the insoluble proteins from mitochondria
could prevent some of the toxic effects of [beta-amyloid] and that’s exactly
what we found,” Anderton said.
Potential
for new therapeutic interventions for Alzheimer’s
MNT also spoke with Verna R. Porter, MD, a
board-certified neurologist and director of the Dementia, Alzheimer’s Disease
and Neurocognitive Disorders at Pacific Neuroscience Institute in Santa Monica,
CA, about this study.
Porter, who was not
involved in the research, said these findings suggest that beta-amyloid likely
contributes to widespread protein insolubility, particularly affecting
mitochondrial proteins and that this insolubility mirrors changes seen in
aging.
“The discovery that targeting mitochondrial health
can mitigate some of these aging effects suggests a potential novel approach to
addressing Alzheimer’s disease,” she added.
Porter said that with the
study’s findings indicating that improving mitochondrial health may reverse
some negative effects of beta-amyloid toxicity, this could pave the way for
several potential interventions including pharmacological approaches, nutritional
supplements, and lifestyle modifications.
“It would be interesting to
conduct clinical trials to test the efficacy of mitochondrial health-boosting
compounds in Alzheimer’s disease patients, including compounds like urolithin A
and other mitochondrial enhancers,” Porter continued.
No comments:
Post a Comment